Latest Breaking News On - Prnewswire kintor pharmaceutical limited - Page 3 : comparemela.com
Completion of Patients Recruitment for Proxalutamide s COVID-19 Hospitalised Study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Completion of Patients Recruitment for Proxalutamide s COVID-19 Hospitalised Study
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, Jan. 28, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the Trial ) of Proxalutamide s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board ( IRB ) of Brazil. The trial was accepted for accelerated review. We have received support from the Brazilian government in terms of medical resources allocation and expect to start with the patients recruitment over the coming weekend.
The Trial is a double-blinded, randomized and multi-center investigational study of Proxalutamide s treatment for hospitalized COVID-19 male and female patients of 18 years old or above. Approximately 588 patients (294 male and 294 female) who meet the eligibility criteria will be enrolled within 48 hours of admission to hospital. The estimated time from screening to the end of the Trial for each patient will be 28 days. The Trial will have two cohorts of
Share this article
Share this article
SUZHOU, China, Jan. 10, 2021 /PRNewswire/ Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to update the preliminary analysis of the clinical trial of Proxalutamide for the treatment of COVID-19 patients. The investigator initiated trial conducted by Dr. Andy Goren and Dr. Flávio Adsuara Cadegiani, shows promising results in the treatment of COVID-19 female outpatients.
This trial commenced the enrolment of 168 female patients on Nov, 2020 after receiving the encouraging results from male patients. Eligible female patients were randomized in a 2:1 ratio to receive either Proxalutamide + standard care (Proxalutamide arm) or Placebo + standard care (Control arm). The co-primary endpoints of the clinical trial are the percentage of subjects hospitalized with COVID-19 and the COVID-19 Ordinal Outcome Scale (a 8-point ordinal scale used by the US National Institute of Allergy and Infection Diseases, such as mechanical ventilation usage and
Kintor Proxalutamide s COVID-19 Clinical Trial Shows Significant Reduction in Hospitalization and Ventilation Rates
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.